Alpha DNA Investment Management LLC Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Alpha DNA Investment Management LLC bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,818 shares of the company's stock, valued at approximately $433,000.

Other large investors have also added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after purchasing an additional 3,537 shares during the period. Barclays PLC raised its stake in Tarsus Pharmaceuticals by 345.9% during the 3rd quarter. Barclays PLC now owns 98,663 shares of the company's stock worth $3,246,000 after buying an additional 76,538 shares during the period. Geode Capital Management LLC boosted its holdings in Tarsus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company's stock worth $27,494,000 after acquiring an additional 62,555 shares in the last quarter. Franklin Resources Inc. grew its stake in Tarsus Pharmaceuticals by 9.3% in the third quarter. Franklin Resources Inc. now owns 12,164 shares of the company's stock valued at $444,000 after acquiring an additional 1,033 shares during the period. Finally, Exome Asset Management LLC bought a new stake in shares of Tarsus Pharmaceuticals during the third quarter valued at approximately $1,500,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Wall Street Analyst Weigh In

TARS has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Barclays decreased their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Guggenheim reaffirmed a "buy" rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, Jefferies Financial Group lifted their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of "Buy" and an average price target of $63.67.

Insiders Place Their Bets

In other news, insider Dianne C. Whitfield sold 2,137 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the transaction, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the sale, the general counsel now directly owns 58,057 shares in the company, valued at $2,687,458.53. This trade represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock worth $1,581,173 over the last quarter. 8.25% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock traded down $0.23 during trading hours on Thursday, hitting $49.77. 250,360 shares of the company's stock traded hands, compared to its average volume of 684,825. The company has a fifty day simple moving average of $47.62 and a 200-day simple moving average of $48.02. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of -13.06 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million for the quarter, compared to analysts' expectations of $58.80 million. Equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.